While, enhanced immunity and sustained clinical responses in NPC patients have been reported [17–19], EBV-encoded proteins such as LMP1 and LMP2 are weakly immunogenic [20] and frequently evolve to acquire mutations within the A2-restricted epitope [21] resulting in either a poor antigen presentation or poor T-cell priming. Here, PSMB9 is linked to nasopharyngeal carcinoma.